Compare Ishares Msci Brazil ETF (EWZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Novartis AG — how do they compare? Ishares Msci Brazil ETF trades at $35.49, while Novartis AG trades at $151.93 (market cap $287.66B). The key difference: Novartis AG pays a 3.14% dividend while Ishares Msci Brazil ETF pays none, and Novartis AG is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| EWZ | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $168.62 |
52-Week Low | $26.52 | $113.50 |
Market Cap | — | $287.66B |
Enterprise Value | — | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ (iShares MSCI Brazil ETF) trades at $35.365, down 1.85% today but maintains a bullish technical outlook with 15 buy signals versus 4 sell signals. The ETF has gained approximately 11% year-to-date, benefiting from Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's $9.92 billion Eco Invest auction and export regulation adjustments to meet EU requirements, supporting economic momentum.
The outlook for EWZ remains positive as Brazil's central bank continues rate cuts from historically high levels, creating favorable conditions for equities. Key risks include dependency on commodity prices and potential economic volatility. Analyst sentiment leans bullish with expectations of further upside from monetary policy support and attractive valuations in Brazilian markets.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
